HALIFAX, June 18, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a
developer of rapid diagnostic technology and solutions, announced today
it has been invited to participate in an exclusive conference taking
place June 19-21, 2012, in Norway focused on both military and civilian
pre-hospital trauma management. The Remote Damage Control
Resuscitation (RDCR) Conference is organized by The Norwegian Naval
Special Operation Commando and the Norwegian Air Ambulance Foundation.
This three day symposium brings together leading military and civilian
medical professionals and researchers in the field to share best
practices on pre-hospital trauma and life-threatening haemorrhage
management.
"This is the first year we have invited both civilian and military
speakers. We recognize that military and civilian pre-hospital trauma
management differs in many ways, but there are probably more issues
that bring us together than pull us apart. We therefore want both
civilian and military perspectives to be presented," said Dr. Geir
Strandenes, Senior Medical Officer with the Norwegian Naval Special
Operation Commando, a leading researcher in pre-hospital whole blood
transfusion, and the principal investigator of the Blood Far Forward
research program.
RDCR involves the assessment and treatment of individuals severely
wounded in the field, either in a combat situation or a civilian
disaster, where evacuation to a hospital is only possible following
stabilization by individuals trained in acute trauma care. In far
forward settings there are no traditional laboratory screening
mechanisms accessible to screen donated blood and previously collected
donor blood is not readily available. It is here that advanced
healthcare tools like MedMira rapid tests become a critical piece of
the RDCR method, where the use of fresh whole blood products may be the
only lifesaving option prior to evacuation.
"Connecting with this world class group of medical, scientific and
research professionals is an excellent opportunity to further
illustrate the unique features of MedMira's advanced rapid diagnostic
technology and the benefits it can bring to both combat casualty care
and civilian disaster preparedness," said Hermes Chan, CEO, MedMira
Inc. "Our ongoing work with the U.S. Army and the Canadian Armed
Forces clearly demonstrates that MedMira rapid diagnostics can play a
critical role in the treatment of individuals critically wounded in
combat. The relationships we have built within these organizations
have led us to this opportunity in Norway and we look forward to
further collaboration with Dr. Strandenes and his colleagues."
To learn more about the RDCR Conference visit www.wholebloodresearch.com.
About MedMira
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
diseases such as HIV and hepatitis B and C in just three minutes. The
company's tests are sold under the Reveal®, Multiplo™ and Miriad brands
in global markets. MedMira's rapid flow-through HIV test is the only
one in the world to achieve regulatory approvals in Canada, the United
States, China and the European Union. MedMira's corporate offices and
manufacturing facilities are located in Halifax, Nova Scotia, Canada.
For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, including
statements relating to growth in the Company's business, earnings and
profitability, and trends in demand for the Company's products, which
involve risk and uncertainties and reflect the Company's current
expectation regarding future events including statements regarding
possible future growth and new business opportunities. Actual events
could materially differ from those projected herein and depend on a
number of factors including, but not limited to, changing market
conditions, successful and timely completion of clinical studies,
uncertainties related to the regulatory approval process, establishment
of corporate alliances and other risks detailed from time to time in
the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.